文献速递流行病学与生物统计临床试验与 GCP

内科疾病住院后静脉血栓栓塞症延长预防:试验序贯与累积荟萃分析

Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis.
PubMed 文献 · PLoS Med · 2019-04-29

该系统评价与荟萃分析纳入5项随机临床试验共40,247例内科住院患者,比较出院后延长血栓预防与标准治疗。延长预防降低症状性静脉血栓栓塞症(VTE)或VTE相关死亡(0.8% vs 1.2%;RR 0.61,95%CI 0.44-0.83;p=0.002),但增加ISTH大出血或致命性出血(0.6% vs 0.3%;RR 2.04,95%CI 1.42-2.91;p<0.001)。

要点

  • 延长血栓预防降低症状性VTE或VTE相关死亡,RR 0.61(95%CI 0.44-0.83)。
  • 延长血栓预防增加ISTH大出血或致命性出血,RR 2.04(95%CI 1.42-2.91)。
  • 预防1例症状性VTE或VTE相关死亡的NNT为250,导致1例大出血或致命性出血的NNH为333。

核心结论

  • 出院后延长血栓预防4至6周可减少症状性或致命性VTE事件,但代价是大出血或致命性出血风险增加。
  • 仍需进一步研究以明确特定内科疾病队列的风险与获益、评估成本效果并制定靶向实施路径。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed/MEDLINE、EMBASE、Cochrane Central和ClinicalTrials.gov自建库至2019年3月21日。
  • 纳入报告延长血栓预防用于VTE预防的随机临床试验(RCT),共5项RCT、40,247例患者(平均年龄67-77岁,女性比例48%-54%,最常见入院原因为心力衰竭)。
  • 延长血栓预防持续时间为24-47天。
  • 进行试验序贯分析和累积荟萃分析。
  • 注册号:PROSPERO CRD42018109151。

主要发现

  • 延长血栓预防组症状性VTE或VTE相关死亡发生率为0.8%,标准治疗组为1.2%;RR 0.61(95%CI 0.44-0.83;p=0.002)。
  • 延长血栓预防组ISTH大出血或致命性出血发生率为0.6%,标准治疗组为0.3%;RR 2.04(95%CI 1.42-2.91;p<0.001)。
  • 预防1例症状性VTE或VTE相关死亡的合并NNT为250(95%CI 167-500)。
  • 导致1例大出血或致命性出血事件的合并NNH为333(95%CI 200-1,000)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入试验在入组标准、个体治疗、延长血栓预防持续时间和VTE检测方案方面存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy, safety, and clinical importance of extended-duration thromboprophylaxis (EDT) for prevention of venous thromboembolism (VTE) in medical patients remain unclear. We compared the efficacy and safety of EDT in patients hospitalized for medical illness. METHODS AND FINDINGS: Electronic databases of PubMed/MEDLINE, EMBASE, Cochrane Central, and ClinicalTrials.gov were searched from inception to March 21, 2019. We included randomized clinical trials (RCTs) reporting use of EDT for prevention of VTE. We performed trial sequential and cumulative meta-analyses to evaluate EDT effects on the primary efficacy endpoint of symptomatic VTE or VTE-related death, International Society on Thrombosis and Haemostasis (ISTH) major or fatal bleeding, and all-cause mortality. The pooled number needed to treat (NNT) to prevent one symptomatic or fatal VTE event and the number needed to harm (NNH) to cause one major or fatal bleeding event were calculated. Across 5 RCTs with 40,247 patients (mean age: 67-77 years, proportion of women: 48%-54%, most common reason for admission: heart failure), the duration of EDT ranged from 24-47 days. EDT reduced symptomatic VTE or VTE-related death compared with standard of care (0.8% versus 1.2%; risk ratio [RR]: 0.61, 95% confidence interval [CI]: 0.44-0.83; p = 0.002). EDT increased risk of ISTH major or fatal bleeding (0.6% versus 0.3%; RR: 2.04, 95% CI: 1.42-2.91; p < 0.001) in both meta-analyses and trial sequential analyses. Pooled NNT to prevent one symptomatic VTE or VTE-related death was 250 (95% CI: 167-500), whereas NNH to cause one major or fatal bleeding event was 333 (95% CI: 200-1,000). Limitations of the study include variation in enrollment criteria, individual therapies, duration of EDT, and VTE detection protocols across included trials. CONCLUSIONS: In this systematic review and meta-analysis of 5 randomized trials, we observed that use of a post-hospital discharge EDT strategy for a 4-to-6-week period reduced symptomatic or fatal VTE events at the expense of increased risk of major or fatal bleeding. Further investigations are still required to define the risks and benefits in discrete medically ill cohorts, evaluate cost-effectiveness, and develop pathways for targeted implementation of this postdischarge EDT strategy. TRIAL REGISTRATION: PROSPERO CRD42018109151.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Bajaj NS, Vaduganathan M, Qamar A, et al. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. PLoS Med. 2019. PMID: 31034476. doi:10.1371/journal.pmed.1002797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。